Preserving the Promise: Improving the Culture of Biotech Investment

Preserving the Promise: Improving the Culture of Biotech Investment critically examines why most biotech startups fail, as they emerge from universities into an ecosystem that inhibits rather than encourages innovation. This Valley of Death squanders our public investments in medical research and with them, the promise of longer and healthier lives. The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies. In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of conventional wisdom that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives. Explains why translation of biotech discovery into medicine succeeds so infrequently that it's been dubbed the Valley of DeathUncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patientsExamines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologiesDeconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better INDICE: Acknowledgements Preface Part 1: The Translation Gap 1. Stop the Madness and Cure Something 2. Into the Valley of Death 3. Clinical Promise vs. Investment Practice 4. Velcade, a Biotech Success Story 5. The Future of Pharma, and Why Biotechnology Matters 6. Connecting Pharma to the Valley of Death 7. Porter's Five Forces and the Market for Angel Capital 8. Out of the Frying Pan 9. Getting to Australia Part 2: Translation Gap 1: Universities Don't Make What Companies Need 10. When is an Experiment Ready for the VoD? 11. Unintended Consequences of Applying for a Patent 12. How Do We Know if It Works? 13. Building a Better Mousetrap Part 3: Translation Gap 1: Good Innovation is not Always a Good Investment 14. Angel Investor Due Diligence 15. Mediators of Angel Investment 16. Investing in Science 17. The Decision to Invest 18. The Terms of the Relationship 19. Investing in the Hockey Stick 20. Harps for Angels 21. Aligning Innovation and Investment Part 4: Translation Gap 2: Technology Transfer Wastes Money and Innovation 22. The Four Conflicts of Technology Transfer 23. Spending Money Nobody Can Afford 24. Embracing Academic Principles Part 5: Epilogue 25. Epilogue

• ISBN: 978-0-12-809216-3
• Editorial: Academic Press
• Encuadernacion: Rústica
• Páginas: 208
• Fecha Publicación: 24/10/2016
• Nº Volúmenes: 1
• Idioma: Inglés